Introduction
Diarrhea is a major cause of morbidity and discomfort for patients undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT) 1 affecting 76-91% of transplant recipients.
1,2
The causes of diarrhea in patients undergoing autologous transplantation include inflammation of the intestinal mucosa owing to chemotherapy, the use of multiple medications such as prophylactic antimicrobials and infection. [3] [4] [5] [6] [7] [8] [9] The incidence of Clostridium difficile-associated diarrhea (CDAD) in patients undergoing APBSCT has been reported to be in the range of 5-7%. 1, 2, 6 A preliminary analysis from our group suggested that patients with multiple myeloma had a higher incidence of CDAD than reported previously. 7 The purpose of this study was to determine the incidence of CDAD in a larger cohort of patients who underwent APBSCT for multiple myeloma and to compare the incidence of CDAD in patients transplanted for multiple myeloma to patients transplanted for lymphoma. We also wanted to identify the risk factors for the development of the CDAD.
Patients and methods
After approval of our local Institutional Review Board, we retrospectively analyzed the cases of 157 consecutive patients who developed diarrhea 1 week before APBSCT and/or 30 days after APBSCT. Transplants were performed as therapy for Hodgkin's and non-Hodgkin's lymphoma or multiple myeloma. All the patients were treated at the Bone Marrow Transplant Unit of the Audie L Murphy Memorial Veterans Hospital (ALMMVH) and the Bone Marrow Transplant Unit of the University Hospital (UH), in San Antonio, TX, USA. Both hospitals are part of the University of Texas Health Science Center at San Antonio Bone Marrow Transplant Program and utilize uniform transplant eligibility criteria and therapeutic protocols. In addition, uniform supportive care protocols are utilized at both hospitals including prophylactic and therapeutic antimicrobial protocols. We analyzed patients with lym-phoma and multiple myeloma who underwent APBSCT during the 5-year period between October 1, 1996 and September 30, 2001. All patients were housed in private rooms, and there were no outbreaks of C. difficile in the Bone Marrow Transplant Units or elsewhere in the hospitals during the study period. Clinical data were obtained through comprehensive review of inpatient and outpatient charts.
The criteria used for inclusion were (1) biopsy-proven diagnosis of Hodgkin's lymphoma, non-Hodgkin's lymphoma or multiple myeloma; (2) APBSCT within the 5-year period between October 1996 and October 2001; and (3) development of diarrhea, defined as discharge of semisolid or liquid stool twice or more during a 24-h period at any time during the 30 days preceding and/or following transplantation. The presence of diarrhea was documented by nursing flow charts and physician and nursing progress notes.
Patient-, disease-and transplant-related parameters analyzed included age, sex, race, Karnofsky performance status, type of underlying malignancy, agents utilized for peripheral blood stem cell (PBSC) mobilization, transplant conditioning regimen, use of hematopoietic growth factor post transplantation, presence and duration of fever defined as oral temperature greater than or equal to 100.51F, presence and duration of neutropenia defined as absolute neutrophil count (ANC) below 500 cells/mm 3 , prophylactic antibiotic regimen, antibiotic treatment for diarrhea, treatment with antibiotic agents given for presumed or documented infections during the study period and the frequency of testing for the presence of C. difficile toxin in stool.
The presence of C. difficile toxin in stool was determined by the Prospect s Clostridium difficile Micro Plate Assay (Prospect II s , Alexon Trend, Ramsey, MN, USA) at both hospitals. This is a qualitative enzyme immunoassay for the detection of C. difficile toxin A in human specimens. During the study period, only toxin A was tested, since toxins A and B were reported to be produced by toxigenic isolates at similar levels. 10 This test has a sensitivity of 84.3% (76.4-90.5) and a specificity of 96.4% (94.9-97.5) (Package insert ProSpect II s ). All patients received prophylactic therapy during APBSCT with antibacterial, antifungal and antiviral agents. Oral ciprofloxacin or levofloxacin was started when the ANC was less than 1000 cells/mm 3 . Ciprofloxacin or levofloxacin was discontinued when the patients became febrile and required empiric, intravenous, broad-spectrum antibiotic therapy or when the ANC exceeded 1000 cells/ mm 3 after engraftment. Trimethoprim/sulfamethoxazole or an equivalent medication, such as dapsone or pentamidine, was given for Pneumocystis jiroveci prophylaxis during the conditioning regimen, and it was discontinued 24 h before the transplant to avoid engraftment delay. Prophylaxis with trimethoprim/sulfamethoxazole was resumed when the ANC reached 500 cells/mm 3 for 2 consecutive days or 30 days after the transplant, whichever occurred first, and was continued until 90 days post transplant. Oral acyclovir was started at the onset of the conditioning regimen and continued until 30 days after the transplant. Fluconazole was initiated once the ANC was below 1000 cells/mm 3 and continued until the ANC was equal or higher than 1000 cells/mm 3 . Fluconazole also was discontinued if the patient required treatment with amphotericin B or any other systemic antifungal agent. If the patient was unable to tolerate oral medications, the prophylactic medications were given intravenously.
Intravenous antibiotic therapy was initiated when patients developed a temperature of 100.51F (37.81C) or higher in the presence of neutropenia. Antibiotic therapy was given following institutional clinical practice guidelines. Typically, this included an intravenous third-or fourth-generation anti-pseudomonal cephalosporin or beta-lactam/beta-lactamase inhibitor antibiotic given as initial empiric therapy. Since 1999, antibiotic cycling that consisted of alternating third-or fourth-generation antipseudomonal cephalosporins with a beta-lactam/betalactamase inhibitor on a monthly basis was utilized at both hospitals. The same antibiotics were utilized each month at both hospitals. Patients in whom central venous catheter infection was suspected also received vancomycin as part of initial therapy. Otherwise, vancomycin was given to persistently febrile patients for 48 h after the initiation of cephalosporin or beta lactam/lactamase inhibitor antibiotic therapy. The antibiotic therapy was modified as blood culture results and organism sensitivities became available.
Fisher's exact test and w 2 test were used to determine if there were significant associations between discrete variables and positive test results. Continuum variables were analyzed using ANOVA. Statistical significance was determined for P-values o0. 05 . We chose not to analyze the data in a multivariate model owing to the small number of events observed.
Results
A total of 242 patients underwent autologous stem cell transplantation during the study period: 115 (47.5%) were transplanted for multiple myeloma and 127 (52.5%) for lymphoma. Of these patients, 205 (84.7%) were male. The mean age was 53 years (range 19-78 years). The age and sex distribution reflects the fact that one of the two participating institutions is a Veterans Hospital, caring mostly for elderly males. One hundred and fifty-seven (64.8%) of the patients transplanted during the study period developed diarrhea. Eighty-four (53.5%) had multiple myeloma and 73 (46.5%) had lymphoma.
One hundred and thirty-five subjects (86%) were tested for C. difficile toxin A, with a total of 328 tests performed ( Table 1) . The remaining 22 patients did not undergo stool examination for C. difficile toxin because of short duration of diarrhea or lack of patient cooperation that precluded obtaining a stool sample for analysis. Twenty-one (15.5%) of the 135 patients tested had positive stool tests for C. difficile and were considered to have CDAD. The incidence of CDAD at ALMMVH was 16% and at UH 10%; this difference was not statistically significant (P ¼ 0.52). Cases of CDAD diagnosed each year were analyzed. Nevertheless, the incidence of CDAD was higher in 1998 (seven cases) and 2000 (nine cases). Those cases were distributed during the course of the year, and no cases were diagnosed at the same time. As expected, the development of diarrhea was most common after transplantation. The median time to development of diarrhea was 4 days after transplant with a range from 6 days before transplantation to 16 days after transplantation. Four patients developed CDAD before transplantation; this occurred after peripheral blood stem cell mobilization at 6, 5 and 2 days before transplant. There was a statistically significant difference between mobilization regimens and development of CDAD (P ¼ 0.01). An analysis pairing the different mobilization regimens and comparing them with the presence of CDAD demonstrated that patients who underwent mobilization with paclitaxel and growth factor had a lower incidence of CDAD when compared to patients who underwent mobilization with growth factor only, or growth factor and cyclophosphamide (P ¼ 0.04 and 0.02, respectively).
Of the 21 patients with C. difficile-positive stools, 14 (66.7%) had myeloma and seven (33.3%) had lymphoma. Fifteen of the 21 patients who tested positive for C. difficile did so in the first stool sample obtained, two in the second sample, three in the third sample and one in the fourth sample. The stage of the disease did not influence the risk of developing diarrhea or C. difficile infection (data not shown).
The average number of antimicrobials administered to the patients who developed C. difficile infection was four with a range of 0-8, including prophylactic therapy for bacterial, fungal or viral infections; this number was similar to the patients with diarrhea not associated with C. difficile. As reported in previous studies, the use of third-generation cephalosporins was associated with CDAD (Table 2) . In this study, we also found an association between the use of intravenous vancomycin and the development of CDAD. Patients who received treatment with vancomycin were febrile for a longer period of time compared to patients who did not require vancomycin therapy. Patients who received vancomycin were febrile for a mean of 6 days in contrast to patients who did not require vancomycin who were febrile for a mean of 4 days (P ¼ 0.005).
Metronidazole was given to 20 patients with confirmed C. difficile infection. One of these patients was switched to oral vancomycin owing to gastrointestinal intolerance of metronidazole, and one patient had resolution of his diarrhea before the test results were obtained. The mean time of treatment was 7 days (range 1-15 days). All patients responded to treatment with complete resolution of the diarrhea.
Discussion
This study confirms that diarrhea remains a frequent complication after autologous stem cell transplantation in patients with lymphoma and multiple myeloma. Approximately two-thirds of the patients who underwent autologous transplantation developed diarrhea. Nevertheless, the incidence of CDAD in patients undergoing APBSCT at our program during the study period was at least twice that reported previously. Despite the fact that there was a difference in the incidence of CDAD between the hospitals, this difference was not statistically significant, and the incidence of CDAD at both hospitals was higher than previously reported. Although it is not possible to determine why the incidence of CDAD was higher in our study, several differences between other studies including patient population, age, the definition of diarrhea and the approach to testing for C. difficile have to be analyzed to determine if they can explain the higher incidence of CDAD seen in our study. First, 90% of our patients were male, and the median age of our patients was 5 and 10 years older than in two previously published reports, which described the age of the population studied. 2, 6 Increasing age has been a consistently noted risk factor, with more than tenfold increased risk for patients older than 60 years of age. 11, 12 Second, our study only included patients with lymphoma and multiple myeloma in contrast to the other two studies, which included patients with other diagnoses. 2, 6 More than half of the patients in the study by Bilgrami et al. 6 had solid tumors, while the study by Tomblyn et al. 2 included patients with other hematologic malignancies. As discussed below, it is not clear if the underlying diagnosis can predispose patients to CDAD. Third, we defined diarrhea as liquid or semisolid stools two or more times in any given 24-h period. Two of the previously published studies 2, 6 defined diarrhea as having semisolid or liquid stools for 2 days instead of 1 day as required in our study. Despite the difference in definition, the overall incidence of diarrhea in our study was similar or lower than previously published studies, suggesting that the difference in definitions did not impact the incidence of diarrhea. Fourth, although the study by Bilgrami et al. utilized a cytotoxicity assay to diagnose CDAD, our study, as well as the Tomblyn and Avery 1 studies, utilized enzyme immunoassays to diagnose CDAD, suggesting that the higher incidence of CDAD in our study is not owing to difference in assay methodology. Finally, it is our policy to test for C. difficile toxin as soon as the patient experiences an episode of nonformed stools. This approach might be different compared to policies of other centers in which testing is deferred until several episodes of diarrhea are experienced by the patient.
One of the aims of our study was to determine if the incidence of CDAD was higher in patients with multiple myeloma when compared to patients with lymphoma. This was based on a preliminary analysis from our group that suggested a higher incidence of CDAD in patients who underwent autologous transplantation for myeloma. 7 Patients with myeloma frequently have hypogammaglobulinemia and defective opsonization. It is conceivable that patients with multiple myeloma could have a higher incidence of CDAD because protection against CDAD seems to be related to serum immunoglobulin G (IgG) antibody directed against toxin A. 13 Patients colonized with C. difficile, who have a high titer of IgG directed against toxin A, have a lower incidence of CDAD.
14 Although the incidence of CDAD was higher in subjects with myeloma than in subjects with lymphoma in our study, this association did not attain statistical significance. A study with a larger number of patients will be necessary to determine if CDAD after autologous stem cell transplantation is more frequent in patients with multiple myeloma.
In our study, the use of third-generation cephalosporins and the use of intravenous vancomycin were associated with the development of CDAD. The use of cephalosporins is widely accepted to predispose to the development of CDAD. For third-generation cephalosporins, an almost perfect correlation was noted between increased use and increases in CDAD, and conversely, a decrease in the incidence of CDAD was associated with decreased use of third-generation cephalosporins. 15 It was somewhat surprising to find that the use of intravenous vancomycin was associated with CDAD in our study. Nevertheless, it has to be kept in mind that most antibiotics, including vancomycin, have been reported to cause CDAD. 16, 17 It is also possible that those patients who received vancomycin were more ill than patients who did not require vancomycin and that the use of vancomycin is a surrogate marker for the general state of the health of the patient, which could have an impact on the incidence of CDAD. As a matter of fact, patients who were treated with vancomycin were febrile for a longer period of time when compared to patients who did not require vancomycin therapy. In our study, we took into account the mobilization regimen, the use of antimicrobials and the incidence of diarrhea for 30 days before transplantation to determine if any of these factors had any influence on the development of CDAD. We found that the use of paclitaxel and hematopoietic growth factor administered as part of the mobilization regimen was associated with a lower incidence of CDAD when compared to patients who received mobilization with hematopoietic growth factor only or hematopoietic growth factor only in combination with cyclophosphamide. This finding was unexpected, since the use of antineoplastic agents has been associated with the development of CDAD. 18 Although the mechanism of how antineoplastic agents can predispose to CDAD has not been completely elucidated, disruption of the intestinal mucosa and alterations in the normal bowel flora are thought to play a major role in the pathophysiology of CDAD in patients treated with chemotherapy. We do not know why patients treated with paclitaxel should have a lower incidence of CDAD. Although the incidence of gastrointestinal toxicity of paclitaxel is low when utilized in doses lower than 390 mg/m 2 , 19 this does not explain why patients who received paclitaxel as part of the conditioning regimen had a lower incidence of CDAD than patients who received hematopoietic growth factor only. It has to be noted that the finding that patients who received paclitaxel as part of the conditioning regimen had a lower incidence of CDAD has to be interpreted cautiously, since only a small number of patients received paclitaxel as part of the mobilization regimen, and this finding might not hold in a larger case series. Finally, we found that more than one stool sample had to be tested for C. difficile toxin to properly rule out CDAD in patients undergoing autologous stem cell transplantation. Testing two samples diagnosed 81% of patients with CDAD, while testing three samples increased the diagnosis rate to 95%. This is in contrast to the study by Tomblyn et al., in which most patients who had one initial negative stool sample for C. difficile proved to have subsequent negative tests. In our experience, performing only one test for C. difficile would have diagnosed only 71% of patients with CDAD.
In summary, diarrhea remains a frequent complication of APBSCT in patients with lymphoma and multiple myeloma. In our experience, the incidence of CDAD was at least twice that which has been reported previously. Factors associated with the development of CDAD were the use of third-generation cephalosporins and the intravenous use of vancomycin. Of interest, patients in whom the hematopoietic stem cell mobilization regimen contained paclitaxel had a lower incidence of CDAD, although the number of patients studied was small. Patients with multiple myeloma had a higher incidence of CDAD, although this did not attain statistical significance. Larger studies will be necessary to determine if patients with myeloma have a higher incidence of CDAD. In our experience, three stool samples had to be tested to be able to diagnose CDAD in 95% of our patients. All patients responded to therapy with resolution of the diarrhea after metronidazole or oral vancomycin therapy.
